Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma.
ICIs
Melanoma
anti-PD1
sequencing
targeted therapy
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
31 05 2022
31 05 2022
Historique:
pubmed:
7
10
2021
medline:
22
7
2022
entrez:
6
10
2021
Statut:
ppublish
Résumé
Cutaneous Melanoma (CM) is an aggressive cancer whose incidence is increasing worldwide. However, the knowledge of its biology and genes driving cell growth and survival allowed to develop new drugs that have improved PFS and OS of advanced disease. Both BRAF targeting agents and immune checkpoint inhibitors (ICIs) have been adopted for the treatment of metastatic disease and the adjuvant setting. Several melanoma patients show innate or acquired drug-resistance and thus new strategies are required for overcoming this complication. New ICIs have been developed, and strategies of combination or sequencing are under investigation in ongoing clinical trials. In addition, pre-clinical data have demonstrated that many strategies induce the release of neoantigens within the tumor microenvironment, thus suggesting the combination of new agents with ICIs. Here, we review the ongoing strategies in advanced CM including a dedicated section on treatment of brain metastases.
Identifiants
pubmed: 34613889
doi: 10.1080/21645515.2021.1980315
pmc: PMC9302493
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1980315Références
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Oncoimmunology. 2018 Jul 23;7(9):e1468955
pubmed: 30228935
Ann Oncol. 2015 Apr;26(4):798-803
pubmed: 25538176
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Sci Transl Med. 2015 Mar 18;7(279):279ra41
pubmed: 25787767
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270
pubmed: 29127120
J Exp Clin Cancer Res. 2019 Oct 17;38(1):419
pubmed: 31623643
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Oncoimmunology. 2016 Oct 14;5(12):e1238557
pubmed: 28123875
Pigment Cell Melanoma Res. 2013 Jul;26(4):499-508
pubmed: 23557327
Eur J Immunol. 1995 Sep;25(9):2718-21
pubmed: 7589152
Lancet. 2020 Jun 13;395(10240):1835-1844
pubmed: 32534646
J Clin Oncol. 2022 May 1;40(13):1428-1438
pubmed: 35030011
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Lancet Oncol. 2012 Sep;13(9):879-86
pubmed: 22894884
J Clin Oncol. 2016 Aug 1;34(22):2619-26
pubmed: 27298410
Clin Cancer Res. 2019 Mar 1;25(5):1462-1471
pubmed: 30377198
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32221017
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33361337
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
Clin Cancer Res. 2017 Apr 15;23(8):1929-1936
pubmed: 27756788
Semin Cancer Biol. 2018 Oct;52(Pt 2):39-52
pubmed: 28987965
Cancer Sci. 2016 Sep;107(9):1193-7
pubmed: 27297395
Oncoimmunology. 2013 Jan 1;2(1):e22890
pubmed: 23483066
Scientifica (Cairo). 2013;2013:857519
pubmed: 24278787
JAMA. 2017 Nov 7;318(17):1647-1648
pubmed: 28885639
Nat Commun. 2017 Mar 27;8:14754
pubmed: 28345650
J Clin Oncol. 2017 Jan 10;35(2):226-235
pubmed: 28056206
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
J Clin Oncol. 2019 Apr 10;37(11):867-875
pubmed: 30811280
Mol Cancer Res. 2006 Oct;4(10):779-92
pubmed: 17050671
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
Cancer. 2019 Nov 1;125(21):3776-3789
pubmed: 31287564
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
PLoS One. 2017 Jul 5;12(7):e0179431
pubmed: 28678791
Clin Cancer Res. 2015 Sep 1;21(17):3969-76
pubmed: 25944800
Clin Cancer Res. 2010 Dec 15;16(24):6040-8
pubmed: 21169256
Cancer Discov. 2020 Aug;10(8):1158-1173
pubmed: 32439653
Cancer Immunol Res. 2014 Apr;2(4):351-60
pubmed: 24764582
Cancer Res. 2017 Jul 15;77(14):3894-3907
pubmed: 28566332
Lancet Oncol. 2016 Jul;17(7):943-955
pubmed: 27269740
Br J Cancer. 2020 Sep;123(6):885-897
pubmed: 32713938
Ann Oncol. 2017 Oct 01;28(10):2581-2587
pubmed: 28961848
Oncoimmunology. 2012 Dec 1;1(9):1476-1483
pubmed: 23264894
Cancer Sci. 2016 Oct;107(10):1373-1379
pubmed: 27486853
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
Cell Res. 2020 Jun;30(6):507-519
pubmed: 32467593
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Int J Oncol. 2018 Sep;53(3):1193-1203
pubmed: 29956749
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
pubmed: 23307859
Front Immunol. 2020 May 15;11:938
pubmed: 32499785